2021年9月，上海慧晓律师事务所正式成为上海生物医药投融资发展基金联盟的会员。由主任及中美执业律师谢晓云领导的上海慧晓律师事务所生命科学团队在生命科学领域深耕十年以上，并具有为辉瑞、赛诺菲、拜耳、勃林格殷格翰、迈蓝、博莱科、梅里埃、因美纳、斯达克、翰辉等多家世界500强、跨国和知名国内医药、医疗器械和消费者保健公司、国际知名医药研发合同外包服务机构和生物医药公司提供并购、投资、公司事务、外包及合作项目、技术转让/许可、临床研究、合同起草和审核、合规或劳动人事法律服务等的丰富专业经验。

In Sept 2021, Shanghai Hui Xiao Law Group becomes a member of Shanghai Bio-Pharma Investment and Financing Development Fund Alliance.  The life science team of Shanghai Hui Xiao Law Group led by Ellen Xie, managing director and lawyer admitted in China and US, has accumulated more than 10 years’ life science practice and rich experience in serving Fortune Global 500s, multinational and leading domestic pharmaceutical, medical device and consumer healthcare corporations as well as international leading contract research organizations (including but not limited to Pfizer, Sanofi, Bayer, Boehringer Ingelheim, Mylan, Bracco, Biomerieux, Illumina, Starkey, Hanhui) in the areas of mergers and acquisitions, foreign direct investment, corporate matters, outsourcing and cooperation projects, technology transfer/licensing, clinical trials, contract review and management, compliance, or labor matters, etc.